Conversely, the occurrence of thyrotoxicosis is reported to be lower, with incidence rates ranging from 0.2%-5.2% for anti-CTLA4 therapy, 0.6%-3.7% for anti-PD-1/PDL1 therapy, and between 8% and 11.1% for combination therapy [19]. Here, CTLA4 is linked to thyrotoxicosis.